Alpha Cognition begins enrolment in RESOLVE Phase IV trial for Zunveyl

​Alpha Cognition has started enrolling patients in its RESOLVE Phase IV study, which is evaluating Zunveyl as a treatment for mild-to-moderate Alzheimer’s.

The post Alpha Cognition begins enrolment in RESOLVE Phase IV trial for Zunveyl appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

Altaris to acquire Simulations Plus in $375m all-cash deal
Distalmotion secures second FDA gynaecology clearance for DEXTER system
Takeda reports pivotal data from FirstLight and RadiantLight trials
FDA approves Bayer’s Ambelvist contrast agent
ALK’s EURneffy secures MHRA approval for anaphylaxis treatment

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us